Eltrombopag 50mg

Eltrombopag 50mg – Quick Overview

Eltrombopag is a prescription medication used to treat low platelet counts (thrombocytopenia) in certain conditions, including chronic immune thrombocytopenia (ITP), hepatitis C-associated thrombocytopenia, and severe aplastic anemia. It works by stimulating the bone marrow to produce more platelets. This medication requires a prescription and close medical supervision.

Medical Supervision & Regulatory Status

Eltrombopag is available only by prescription in the United States and is regulated by the FDA. It carries an FDA boxed warning regarding the risk of liver toxicity and requires regular blood monitoring, including platelet counts and liver function tests, before and during treatment.

Clinical Context

Thrombocytopenia (low platelet count) can significantly increase the risk of bruising and bleeding, ranging from minor issues to serious, life-threatening hemorrhage in severe cases. Conditions like chronic ITP, an autoimmune disorder where the body destroys its own platelets, or aplastic anemia, where the bone marrow fails to produce enough blood cells, often require treatment when platelet counts fall to unsafe levels or bleeding symptoms occur.

Eltrombopag represents a class of medications that address the underlying production problem by stimulating platelet formation, rather than relying solely on immune-suppressing therapies or platelet transfusions, which provide only temporary relief. This approach is particularly valuable for patients who haven’t responded adequately to first-line treatments such as corticosteroids or immunoglobulins.

Eltrombopag fits into treatment as an option for patients with chronic or refractory thrombocytopenia, used under specialist (typically hematologist) supervision given the need for careful dose titration and monitoring.

How Eltrombopag Works

Eltrombopag belongs to the drug class of thrombopoietin receptor agonists. It works by binding to and activating the thrombopoietin receptor on bone marrow cells, mimicking the action of the body’s natural hormone that regulates platelet production.

By activating this receptor, eltrombopag stimulates the proliferation and maturation of megakaryocytes, the bone marrow cells responsible for producing platelets, which leads to increased platelet counts in the blood. This mechanism directly addresses the underlying production deficit in conditions like ITP and aplastic anemia, rather than simply managing symptoms.

What is Eltrombopag?

• Drug Class: Thrombopoietin receptor agonist
• Active Ingredient: Eltrombopag 50mg (as eltrombopag olamine)
• Mechanism: Activates thrombopoietin receptors to stimulate platelet production
• Form: Oral tablet
• Dosing Frequency: Once daily
• Regulatory Status: Prescription only (US); FDA boxed warning present

Uses / Indications

Chronic Immune Thrombocytopenia (ITP): Approved for patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Hepatitis C-Associated Thrombocytopenia: Approved to help initiate and maintain interferon-based therapy in patients with chronic hepatitis C and low platelet counts.

Severe Aplastic Anemia: Approved for patients with severe aplastic anemia who have had an insufficient response to prior immunosuppressive therapy.

How to Use / Dosage

Your doctor determines your starting dose based on your specific condition, platelet count, and, for certain patients (such as those of East Asian ancestry or with liver impairment), adjusted starting doses. Tablets are typically taken once daily on an empty stomach, at least one hour before or two hours after eating, and must be taken separately from calcium-rich foods, antacids, and mineral supplements (such as iron, calcium, magnesium, aluminum, selenium, and zinc), as these significantly reduce absorption.

If you miss a dose, skip it and take your next dose at the regular scheduled time—do not double up. Do not stop taking this medication suddenly without consulting your provider, and never adjust your dose on your own, as dosing is carefully titrated based on regular platelet count monitoring.

Side Effects

Most people tolerate eltrombopag reasonably well, though side effects can occur, and regular monitoring is essential.

Common side effects may include headache, nausea, diarrhea, upper respiratory infection symptoms, and muscle aches.

Serious side effects, though less common, can include liver toxicity, increased risk of blood clots, worsening of bone marrow changes, cataracts, and, in patients with hepatitis C, worsening or relapse of liver-related complications.

Emergency Warning Signs — Seek immediate medical care if you experience:

• Yellowing of the skin or eyes, dark urine
• Unusual fatigue or right upper abdominal pain
• Signs of a blood clot (leg swelling, pain, chest pain, shortness of breath)
• Unusual or excessive bruising or bleeding
• Vision changes
• Signs of a severe allergic reaction (swelling, difficulty breathing)

Warnings & Precautions

Eltrombopag carries an FDA boxed warning for the risk of hepatotoxicity (liver damage), requiring liver function tests before starting treatment and periodically throughout therapy; dose adjustment or discontinuation may be needed if liver enzymes rise significantly. It is contraindicated in patients with known hypersensitivity to eltrombopag.

This medication carries an increased risk of blood clots (thrombotic/thromboembolic events), particularly in patients with chronic liver disease, so your provider will weigh this risk when determining your treatment plan and platelet count targets. Eltrombopag interacts significantly with medications and supplements containing polyvalent cations (calcium, iron, magnesium, aluminum, selenium, zinc), which must be taken at least 4 hours apart to avoid reduced drug absorption; it also interacts with certain statins (such as rosuvastatin) and drugs metabolized by specific liver enzymes. Use during pregnancy should be discussed carefully with a provider, as data are limited, and breastfeeding is generally not recommended during treatment. In patients with aplastic anemia, regular monitoring for new chromosomal abnormalities in bone marrow cells is also recommended during treatment. Regular eye examinations may be recommended to monitor for cataract development with long-term use.

Who Should Not Use This Medication

• Known hypersensitivity to eltrombopag
• Severe, uncontrolled liver disease (without specialist evaluation)
• Active or high risk of blood clots (without careful specialist evaluation)
• Uncontrolled significant hepatic impairment
• Patients requiring concurrent use of interacting supplements without proper spacing (relative precaution)

Storage Instructions

Store at room temperature (68-77°F/20-25°C), away from excess heat, moisture, and light. Keep in the original container. Store out of reach of children and pets.

Frequently Asked Questions

Is a prescription required for Eltrombopag?

Yes, a prescription is required in the United States, and this medication requires specialist (typically hematologist) supervision with regular blood monitoring.

How long does it take to work?

Platelet counts are usually checked weekly during initial dose adjustment, with responses often seen within 1-2 weeks, though optimal dosing may take several weeks to establish. Your provider will monitor your response closely.

Is it safe to stop taking this medication suddenly?

Stopping should always be discussed with your provider, as platelet counts can drop again after discontinuation, sometimes below pre-treatment levels. Your provider will guide any changes to your treatment plan.

What medications interact with this drug?

Calcium, iron, and other mineral supplements, certain statins, and drugs metabolized by specific liver enzymes can significantly interact with eltrombopag. Always share your full medication and supplement list with your provider or pharmacist, and space mineral supplements at least 4 hours apart from this medication.

What should I do if I miss a dose?

Skip the missed dose and take your next dose at your regular scheduled time. Do not take two doses at once.

What is the cost without insurance?

The cost without insurance depends on the seller, brand availability, and pack size, and may also vary by location and available discounts. Patient assistance programs may be available given the specialized nature of this medication.

How can I order this medication online?

A valid prescription from your specialist is required to order this medication. Typically, your doctor submits the prescription to a licensed specialty pharmacy, which then ships it to your home; always verify the pharmacy is licensed before ordering.

Is this medication available over the counter?

No, it is not available over the counter. This medication requires specialist prescribing and regular monitoring due to its boxed warning and significant interaction profile.

Resources

• FDA Prescribing Information (Eltrombopag/Promacta): https://www.accessdata.fda.gov/scripts/cder/daf/
• MedlinePlus Drug Information: https://medlineplus.gov/druginfo/meds/a608029.html
• National Organization for Rare Disorders – Aplastic Anemia: https://rarediseases.org/rare-diseases/aplastic-anemia/

References

1. MedlinePlus (NIH) – Eltrombopag: https://medlineplus.gov/druginfo/meds/a608029.html
2. DailyMed (NIH) – Eltrombopag Label: https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=eltrombopag
3. FDA Drug Approvals – Eltrombopag: https://www.accessdata.fda.gov/scripts/cder/daf/

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified specialist or physician before using eltrombopag.